Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.57 |
| ▸ | CNR2 | P34972 | 7/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | MLYCD | O95822 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4254640 | 0.96 | CNR1 (0.58) | CNR1CNR2P2RX7ADORA2AADORA1 | |
| SCHEMBL4253583 | 0.88 | CNR1 (0.60) | CNR1CNR2 | |
| SCHEMBL14284345 | 0.85 | CNR1 (0.58) | CNR1CNR2P2RX7HDAC6MLYCD | |
| SCHEMBL5239059 | 0.80 | PIM1 (0.49) | PIM1PIM3 | |
| SCHEMBL30131489 | 0.80 | P2RX7 (0.58) | CNR1CNR2P2RX7 | |
| SCHEMBL5233590 | 0.79 | CNR1 (0.75) | CNR1CNR2 | |
| SCHEMBL5231512 | 0.78 | HCRTR2 (0.49) | CNR1CNR2PIM1PIM3 | |
| SCHEMBL5259572 | 0.77 | NPC1 (0.60) | CNR1CNR2P2RX7MEN1KMT2A | |
| SCHEMBL5230582 | 0.76 | CNR1 (0.60) | CNR1CNR2P2RX7 | |
| SCHEMBL6172165 | 0.75 | GRM4 (0.50) | P2RX7PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070219254-A1 | Therapeutic Compounds: Pyridine N-Oxide Scaffold | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | disclosed |
| US-20070219254-A1 | Therapeutic Compounds: Pyridine N-Oxide Scaffold | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | disclosed |
| US-20070219254-A1 | Therapeutic Compounds: Pyridine N-Oxide Scaffold | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | disclosed |
| CN-101001840-A | Therapeutic compounds: pyridines as skeletons | ASTRAZENECA AB (SE) | 2007-07-18 | — | — | CN | disclosed |
| CN-1956959-A | Therapeutic compounds: pyridine N oxide scaffold | ASTRAZENECA AB (SE) | 2007-05-02 | — | — | CN | disclosed |
| EP-1756060-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1756061-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE N OXIDE SCAFFOLD | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005115986-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005115987-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE N OXIDE SCAFFOLD | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219254-A1 | Therapeutic Compounds: Pyridine N-Oxide Scaffold | OPRM1, OPRL1, OPRD1 | CNR1 9/4885CNR2 16/4885P2RX7 33/4885 |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | OPRL1, OPRK1, P2RX3 | CNR1 6/4885CNR2 11/4885P2RX7 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.